Essential Pharma
Essential Pharma is a UK-based privately held specialty pharmaceutical company that acquires, maintains, and commercialises clinically differentiated, at-risk medicines for small and rare disease patient populations across approximately 70 countries, with a growing development pipeline.
- Company typePrivate
- Founded1985
- HeadquartersEgham, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Essential Pharma does
Essential Pharma is a privately held specialty pharmaceutical company headquartered in Egham, Surrey, UK, focused on acquiring, maintaining, and commercialising clinically differentiated medicines that serve small, underserved, or rare disease patient populations across approximately 70 countries. Founded around 1985 and backed by Swiss private equity firm Gyrus Capital since a 2020 management buyout, the company operates a portfolio of more than 35 products spanning 12 therapeutic areas — with particular depth in CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, and rare disease. Its core business model is the acquisition of mature, at-risk-of-discontinuation assets divested by larger pharmaceutical companies (notably from Novartis, Teva, Bayer, and Rosemont Pharmaceuticals), combined with selective development of novel therapies for high-unmet-need indications.
The company's commercial engine combines direct sales operations in five European jurisdictions (UK, France, Malta, Switzerland, Spain) with regional distribution partnerships — Clinigen for JAPAC and AcedrA Biopharmaceuticals for MENA. Pricing is not publicly disclosed but is negotiated through regional reimbursement frameworks typical of niche specialty pharmaceuticals. In April 2024 the company made its most significant strategic shift by acquiring Renaissance Pharma Ltd, introducing its first development-stage asset: Daretabart (hu1418K322A), a structurally modified anti-GD2 monoclonal antibody for high-risk neuroblastoma licensed exclusively from St. Jude Children's Research Hospital, which received FDA Fast Track Designation and IND clearance in April 2026. Essential Pharma is organised into Established Brands and Rare Disease business units, led by a senior team drawn from Jazz Pharmaceuticals, GSK, EUSA Pharma, Alexion, and Catalent. A €900 million recapitalisation in December 2024 led by AlpInvest and Sixth Street provides capital for continued acquisitions and pipeline expansion.
Essential Pharma firmographics
Firmographics- Name
- Essential Pharma
- Legal name
- Essential Holdings Limited
- Website
- https://essentialpharmagroup.com
- Company type
- Private
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Essential Pharma is a UK-based privately held specialty pharmaceutical company that acquires, maintains, and commercialises clinically differentiated, at-risk medicines for small and rare disease patient populations across approximately 70 countries, with a growing development pipeline.
- Ownership category
- akta.pro rank
Essential Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where Essential Pharma is headquartered
LocationHeadquarters
- HQ city
- Egham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices5 records
Markets served
Essential Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Essential Pharma generates revenue through the sale and commercialization of acquired specialty pharmaceutical products across multiple therapeutic areas including rare disease, CNS, ophthalmology, and gastroenterology. Products are sold in approximately 70 countries through direct sales and distribution partners.
- In-licensing and Out-licensing: The company enters into licensing arrangements for products, including in-licensing arrangements for development-stage and commercial products, and out-licensing to maximize value of assets while ensuring patient access.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels4 records
Essential Pharma product offering
Product offeringCore offering
Essential Pharma acquires, manufactures and commercializes clinically differentiated, niche branded pharmaceutical medicines that are at risk of discontinuation by larger pharmaceutical companies, serving small, underserved and rare disease patient populations across approximately 70 countries. The portfolio spans more than 35 products across 12 therapeutic areas (rare disease, CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, endocrinology, gynaecology, infectious diseases, rheumatology). In parallel, the company is developing its first clinical-stage asset, Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma.
Differentiator
Problem solved
Functional benefit
Products and services
- Ventavis (iloprost trometamol) Inhaled iloprost therapy used to treat adult primary pulmonary hypertension; marketed to specialist pulmonary vascular centers in over 60 markets globally.
- Daretabart (hu1418K322A) Novel anti-GD2 monoclonal antibody in clinical development for high-risk neuroblastoma (7–10% of all childhood cancers); held under exclusive license from St. Jude Children's Research Hospital via subsidiary Renaissance Pharma.
- Iopidine Ophthalmic product for the adjunctive treatment of glaucoma, sold to eye care specialists across markets outside the US and India.
- Methergine Established therapy for the treatment of post-partum hemorrhage, distributed to obstetric and maternity healthcare providers across markets outside the US and India.
- Colobreathe (colistimethate sodium) Inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients; sold to respiratory and CF treatment centers across Europe.
- Reminyl (galantamine hydrobromide) oral capsules Established CNS therapy for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type; prescribed by neurologists and geriatric specialists.
- Priadel Established lithium-based CNS therapy supplied to the UK market as an essential medicine for eligible patient populations.
Quantifiable outcome
- Daretabart demonstrated 73.7% 3-year event-free survival and 86.0% overall survival in Phase II trials for high-risk neuroblastoma
- +1 more outcomes
Companies that use Essential Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
Essential Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Essential Pharma partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- Bayer AGcoreAcquisition of Ventavis (iloprost trometamol) and Breelib nebuliser delivery technology from Bayer AG, expanding Essential Pharma's rare disease franchise. Rights acquired across all global markets excluding USA and Russia.
- ClinigenmajorExpanded collaboration to improve patient access in JAPAC region. Drives continued patient access to four important therapies in Japan and Korea, strengthening combined market presence.
- International Health PartnersminorCampaign to donate life-saving medicines to disaster-hit countries. Donations to help support over 30,000 patients in disaster-hit and vulnerable communities worldwide.
- AGC BiologicscoreManufacturing agreement for late phase clinical manufacturing of immunotherapy candidate (Daretabart) for high-risk neuroblastoma treatment.
- Renaissance Pharma LtdcoreAcquisition of Renaissance Pharma Ltd, a UK-based biopharmaceutical company developing anti-GD2 antibody (Hu14.18) for neuroblastoma treatment. Focus on advancing EU/US market approval of Phase II candidate.
- AcedrA BiopharmaceuticalsmajorDistribution agreement to commercialize essential medicines in the Middle East and North Africa region.
- TevamajorAcquisition of European rights to Colobreathe (colistimethate sodium), an inhaled antibiotic for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.
- NovartismajorAcquisition of worldwide rights (excluding US and India) to Iopidine for glaucoma treatment and Methergine for post-partum haemorrhage from Novartis.
- St. Jude Children's Research HospitalcoreExclusive license agreement for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma. The antibody targets GD2, a cell surface antigen highly expressed on neuroblastoma cells.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Essential Pharma competitors and assessment
Company assessmentBroad incumbents
- Viatris: Global specialty and generics pharma formed by the Mylan-Pfizer Upjohn merger, with a large established-brand and off-patent specialty portfolio. Essential Pharma's Established Brands President previously served as Country Manager Switzerland/Liechtenstein at Viatris, and the companies address overlapping customers in mature specialty categories.
- Aspen Pharmacare: South African-headquartered specialty pharma with a global portfolio in branded generics, specialty branded, and rare-disease medicines. Comparable as a platform that has built scale through large pharma divestments and operates a similar established-brand plus specialty mix.
- Jazz Pharmaceuticals: Specialty pharma with a CNS, rare disease, and sleep-medicine focus, built significantly through acquisitions (including EUSA Pharma in 2012). Multiple Essential Pharma executives previously worked at Jazz, and the company is a direct reference point for the EUSA-style growth playbook.
- Leo Pharma: Danish specialty pharma with a dermatology-led portfolio and growing rare-disease presence. One of Essential Pharma's VPs previously held senior commercial roles at Leo, and the two share a European specialty-pharma orientation.
- Mundipharma: Privately held specialty pharma with established-brand and specialty portfolios across pain, oncology, and rare disease. One of Essential Pharma's M&A leaders previously held business development roles at Mundipharma, and the companies share a niche-portfolio and European distribution model.
- Swedish Orphan Biovitrum (Sobi): Swedish-listed rare-disease specialty pharma with a portfolio of niche and orphan therapies across multiple therapeutic areas, including immunology. Comparable in rare-disease focus, geographic mix (predominantly Europe/US), and bolt-on M&A strategy.
- Recordati: Italian specialty pharma group with a strong rare disease and established-brand portfolio across Europe. Acquired EUSA Pharma for €750M in 2022 (founded by Essential Pharma's current Chairman and CEO) and is a direct comparator on business model and exit pathway.
Direct peers
- Theramex: UK-based specialty pharma focused on women's health and other niche therapeutic areas, built largely through product acquisitions from larger pharma. Comparable niche-portfolio strategy and target-therapeutic mix (e.g., Methergine for postpartum hemorrhage overlaps with Essential Pharma's gynecology franchise).
- Clinigen Group: UK-headquartered specialty pharma focused on accessing, registering, and distributing niche and at-risk medicines. Closely comparable operating model, with overlapping therapeutic areas and a direct commercial partnership with Essential Pharma in JAPAC.
Emerging players
- Leadiant Biosciences: US-headquartered rare-disease specialty pharma with a portfolio of niche therapies for underserved populations. Essential Pharma's interim CEO previously served as Global Head of Business Development at Leadiant, and the two share a rare-disease and specialty-orphan commercial focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Essential Pharma social profiles
Digital presenceEssential Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Essential Pharma leadership team
Management profileNumber of profiles
Profiles16 records
Essential Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Essential Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Essential Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Essential Pharma
What does Essential Pharma do?
Essential Pharma acquires, manufactures and commercializes clinically differentiated, niche branded pharmaceutical medicines that are at risk of discontinuation by larger pharmaceutical companies, serving small, underserved and rare disease patient populations across approximately 70 countries. The portfolio spans more than 35 products across 12 therapeutic areas (rare disease, CNS, ophthalmology, gastroenterology, cardiovascular, dermatology, endocrinology, gynaecology, infectious diseases, rheumatology). In parallel, the company is developing its first clinical-stage asset, Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody for high-risk neuroblastoma.
Is Essential Pharma a public or private company?
Essential Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Essential Pharma founded?
Essential Pharma was founded in 1985. It employs 101 to 250 people.
Where is Essential Pharma based?
Essential Pharma is headquartered in Egham, United Kingdom, in the Europe region.
How does Essential Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are in-licensing and Out-licensing.
Who are Essential Pharma's main competitors?
Broad incumbents on record are Viatris, Aspen Pharmacare, Jazz Pharmaceuticals, Leo Pharma, Mundipharma, Swedish Orphan Biovitrum (Sobi) and Recordati. Direct peers are Theramex and Clinigen Group. Leadiant Biosciences is listed as an emerging player.
Does Essential Pharma have an API?
No public API is recorded for Essential Pharma.
What industry is Essential Pharma in?
Essential Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.